Clinical Trials
274 trialsNCT07226349 2026-05-27
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT07414836 2026-05-27
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT07128303 2026-05-26
Study of GS-5319 in Adults With Solid Tumors
Gilead Sciences
Phase 1 Recruiting
NCT05981703 2026-05-22
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06589596 2026-05-22
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06598800 2026-05-22
Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT05329103 2026-05-15
A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors
Peel Therapeutics Inc
Phase 1 Recruiting
NCT05901285 2026-05-14
Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors
Vaxiion Therapeutics
Phase 1 Recruiting
NCT07182591 2026-05-14
A Study of DS5361b in Participants With Advanced Solid Tumors
Daiichi Sankyo
Phase 1 Recruiting
NCT07582822 2026-05-13
JH021 in Patients With Advanced Solid Tumors or EGFR-Mutant NSCLC
Biotech Pharmaceutical Co., Ltd.
Phase 1 Not yet recruiting
NCT06625593 2026-05-11
A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT05824663 2026-05-04
A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of HBM1020 in Subjects With Advanced Solid Tumors
Harbour BioMed US, Inc.
Phase 1 Completed
NCT05300048 2026-04-30
Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations
Faeth Therapeutics
Phase 1 Terminated
NCT05687682 2026-04-28
Safety of AM-928 Infusion in Advanced Solid Tumors
AcadeMab Biomedical Inc.
Phase 1 Recruiting
NCT06260514 2026-04-23
ACESOT-1051
Aprea Therapeutics
Phase 1 Recruiting
NCT05036291 2026-04-22
A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors
Ningbo Newbay Technology Development Co., Ltd
Phase 1 Terminated
NCT04855656 2026-04-20
MYTHIC
Debiopharm International SA
Phase 1 Recruiting
NCT06597721 2026-04-17
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
Adcendo ApS
Phase 1 Recruiting
NCT07380334 2026-04-16
A Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-1049 in Patients With Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Recruiting
NCT06233942 2026-04-15
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06220864 2026-04-14
SNV1521 in Participants With Advanced Solid Tumors
Synnovation Therapeutics, Inc.
Phase 1 Recruiting
NCT06143774 2026-04-13
Study of TRX-920 for Patients With Advanced Solid Tumors
TaiRx, Inc.
Phase 1 Recruiting
NCT06352359 2026-04-13
Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors
OncoC4, Inc.
Phase 1 Recruiting
NCT07408258 2026-04-13
Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors
OncoC4, Inc.
Phase 1 Not yet recruiting
NCT06130254 2026-04-09
Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT06422520 2026-04-06
A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Active not recruiting
NCT06672185 2026-04-03
ARC101 in Advanced Solid Tumors
Third Arc Bio
Phase 1 Recruiting
NCT04735978 2026-02-27
Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours
Replimune, Inc.
Phase 1 Active not recruiting
NCT04649385 2026-02-20
BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Active not recruiting
NCT05638334 2026-02-17
Immuno-positron Emission Tomography Study of 89Zr-S095012 in Patients With Advanced Solid Tumours
Servier
Phase 1 Terminated
NCT06973863 2026-02-13
A Study of PEP08 in Patients With MTAP-Del Advanced or Metastatic Solid Tumors
PharmaEngine
Phase 1 Recruiting
NCT06750185 2026-02-11
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
BioNTech SE
Phase 1 Recruiting
NCT05478486 2026-02-04
Assessment of Safety, Tolerability and PK Profile of MSP008-22 in Patients With Advanced Solid Tumours
Godavari Biorefineries Limited
Phase 1 Completed
NCT06244485 2026-02-04
A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
Daiichi Sankyo
Phase 1 Recruiting
NCT05352750 2026-02-03
Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors
Sonnet BioTherapeutics
Phase 1 Active not recruiting
NCT06993116 2026-01-28
A Phase I Study of SHR-4712 in Patients With Advanced Solid Tumors
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 1 Active not recruiting
NCT06334783 2026-01-21
TIL for Patients With Advanced Solid Tumor
Hervor Therapeutics
Phase 1 Terminated
NCT07348653 2026-01-21
A Study of MG2512 Injection in Participants With Advanced Solid Tumors
Shanghai Mabgen Biopharmaceutical Technology Co., Ltd.
Phase 1 Not yet recruiting
NCT06302426 2026-01-16
Trial of INI-4001 in Patients With Advanced Solid Tumours
Inimmune Corporation
Phase 1 Recruiting
NCT06560632 2026-01-16
POLAR
Repare Therapeutics
Phase 1 Terminated
NCT06859762 2026-01-14
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1 Recruiting
NCT06298058 2026-01-07
A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients.
Shanghai Institute Of Biological Products
Phase 1 Recruiting
NCT06512116 2026-01-07
A Clinical Trial of SIBP-A17 Injection in the Treatment of Advanced Solid Tumor Patients.
Shanghai Institute Of Biological Products
Phase 1 Recruiting
NCT05007782 2025-12-29
Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors
Gilead Sciences
Phase 1 Recruiting
NCT06328673 2025-12-24
A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
D2M Biotherapeutics Inc.
Phase 1 Active not recruiting
NCT05306132 2025-12-23
Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT04936178 2025-12-22
A Study of NB003 in Patients With Advanced Malignancies
Ningbo Newbay Technology Development Co., Ltd
Phase 1 Completed
NCT06509906 2025-12-18
M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)
EMD Serono
Phase 1 Terminated
NCT06241456 2025-12-09
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Recruiting
NCT05155722 2025-12-08
Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT1308 in Advanced Solid Tumors
Bio-Thera Solutions
Phase 1 Completed